Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hTERT mRNA DC Vaccine in Metastatic Prostate Cancer
NCT01153113Phase 2Withdrawn
- Sponsor
- University of Florida
- Start
- Jan 2008
- Primary completion
- Dec 2009
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
01
Overview
A Phase 2 trial of hTERT-DC vaccine in Metastatic Prostate Cancer (mPC), sponsored by University of Florida. Planned start Jan 2008; status: withdrawn.
02
Drugs
hTERT-DC vaccine
03
Conditions
Metastatic Prostate Cancer (mPC)
Beyond the preview
Go deeper on NCT01153113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01153113.